{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:46:17Z","timestamp":1789987577991,"version":"4.0.1"},"reference-count":131,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,2,25]],"date-time":"2019-02-25T00:00:00Z","timestamp":1551052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.00104","type":"journal-article","created":{"date-parts":[[2019,2,25]],"date-time":"2019-02-25T14:08:47Z","timestamp":1551103727000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":75,"title":["Progress in EBV Vaccines"],"prefix":"10.3389","volume":"9","author":[{"given":"Dwain G.","family":"van Zyl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Mautner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri-Jacques","family":"Delecluse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,2,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1146\/annurev-pathmechdis-012418-013023","article-title":"Epstein\u2013Barr virus and cancer Ann Rev Pathol","volume":"14","author":"Farrell","year":"2019"},{"key":"B2","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S0140-6736(64)91524-7","article-title":"Virus particles in cultured lymphoblasts from burkitt's lymphoma","volume":"1","author":"Epstein","year":"1964","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/216810a0","article-title":"Establishment of cell lines from peripheral leucocytes in infectious mononucleosis","volume":"216","author":"Pope","year":"1967","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ijc.2910030619","article-title":"Transformation of foetal human keukocytes in vitro by filtrates of a human leukaemic cell line containing herpes-like virus","volume":"3","author":"Pope","year":"1968","journal-title":"Int J Cancer"},{"key":"B5","volume-title":"Epstein-Barr Virus","author":"Longnecker","year":"2013"},{"key":"B6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/B978-0-12-800098-4.00006-4","article-title":"Dynamic Epstein-Barr virus gene expression on the path to B-cell transformation","volume":"88","author":"Price","year":"2014","journal-title":"Adv Virus Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1128\/JVI.01512-10","article-title":"A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas","volume":"85","author":"Ma","year":"2011","journal-title":"J Virol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.chom.2012.06.008","article-title":"An atlas of the Epstein-Barr virus transcriptome and epigenome reveals host-virus regulatory interactions","volume":"12","author":"Arvey","year":"2012","journal-title":"Cell Host Microbe"},{"key":"B9","doi-asserted-by":"publisher","first-page":"14257","DOI":"10.1038\/ncomms14257","article-title":"Epstein-Barr virus particles induce centrosome amplification and chromosomal instability","volume":"8","author":"Shumilov","year":"2017","journal-title":"Nat Commun."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1093\/nar\/gky129","article-title":"Translational profiling of B cells infected with the Epstein-Barr virus reveals 5' leader ribosome recruitment through upstream open reading frames","volume":"46","author":"Bencun","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S1074-7613(02)00318-7","article-title":"The dispersal of mucosal memory B cells: evidence from persistent EBV infection","volume":"16","author":"Laichalk","year":"2002","journal-title":"Immunity"},{"key":"B12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/infdis\/jis646","article-title":"Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students","volume":"207","author":"Balfour","year":"2013","journal-title":"J Infect Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1038\/cti.2015.1","article-title":"Infectious mononucleosis","volume":"4","author":"Balfour","year":"2015","journal-title":"Clin Transl Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S0002-9343(00)00560-X","article-title":"Acute infectious mononucleosis: characteristics of patients who report failure to recover","volume":"109","author":"Buchwald","year":"2000","journal-title":"Am J Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1158\/0008-5472.CAN-06-3566","article-title":"Infectious mononucleosis, childhood social environment, and risk of Hodgkin lymphoma","volume":"67","author":"Hjalgrim","year":"2007","journal-title":"Cancer Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e12496","DOI":"10.1371\/journal.pone.0012496","article-title":"An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis","volume":"5","author":"Handel","year":"2010","journal-title":"PLoS ONE"},{"key":"B17","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1146\/annurev.pathol.1.110304.100209","article-title":"Spectrum of Epstein-Barr virus-associated diseases","volume":"1","author":"Kutok","year":"2006","journal-title":"Annu Rev Pathol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/ajt.12004","article-title":"Epstein-Barr virus infection and posttransplant lymphoproliferative disorder","volume":"13","author":"Green","year":"2013","journal-title":"Am J Transplant."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S0024-3205(99)00214-3","article-title":"A model for persistent infection with Epstein-Barr virus: the stealth virus of human B cells","volume":"65","author":"Thorley-Lawson","year":"1999","journal-title":"Life Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1086\/523813","article-title":"Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults","volume":"196","author":"Sokal","year":"2007","journal-title":"J Infect Dis."},{"key":"B21","first-page":"171","article-title":"First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen","volume":"84","author":"Gu","year":"1995","journal-title":"Dev Biol Stand."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1097\/TP.0b013e3181b9d918","article-title":"A phase I trial of epstein-barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation","volume":"88","author":"Rees","year":"2009","journal-title":"Transplantation"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1128\/JVI.01409-07","article-title":"Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis","volume":"82","author":"Elliott","year":"2008","journal-title":"J Virol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1038\/cti.2015.4","article-title":"Epstein-barr virus vaccines","volume":"4","author":"Cohen","year":"2015","journal-title":"Clin Transl Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"16286","DOI":"10.1073\/pnas.0407320101","article-title":"Proteins of purified Epstein-Barr virus","volume":"101","author":"Johannsen","year":"2004","journal-title":"Proc Natl Acad Sci USA."},{"key":"B26","doi-asserted-by":"publisher","first-page":"4510","DOI":"10.1073\/pnas.81.14.4510","article-title":"Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2","volume":"81","author":"Fingeroth","year":"1984","journal-title":"Proc Natl Acad Sci USA."},{"key":"B27","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.celrep.2013.01.023","article-title":"Human complement receptor type 1\/CD35 is an Epstein-Barr Virus receptor","volume":"3","author":"Ogembo","year":"2013","journal-title":"Cell Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"13557","DOI":"10.1038\/ncomms13557","article-title":"Structural basis for Epstein-Barr virus host cell tropism mediated by gp42 and gHgL entry glycoproteins","volume":"7","author":"Sathiyamoorthy","year":"2016","journal-title":"Nat Commun."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e1004309","DOI":"10.1371\/journal.ppat.1004309","article-title":"Assembly and architecture of the EBV B cell entry triggering complex","volume":"10","author":"Sathiyamoorthy","year":"2014","journal-title":"PLoS Pathog."},{"key":"B30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nm830","article-title":"Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells","volume":"9","author":"Tugizov","year":"2003","journal-title":"Nat Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41564-017-0081-7","article-title":"Ephrin receptor A2 is a functional entry receptor for Epstein-Barr virus","volume":"3","author":"Chen","year":"2018","journal-title":"Nat Microbiol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/s41564-017-0080-8","article-title":"Ephrin receptor A2 is an epithelial cell receptor for Epstein-Barr virus entry","volume":"3","author":"Zhang","year":"2018","journal-title":"Nat Microbiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"20464","DOI":"10.1073\/pnas.0907508106","article-title":"Fusion of epithelial cells by Epstein-Barr virus proteins is triggered by binding of viral glycoproteins gHgL to integrins alphavbeta6 or alphavbeta8","volume":"106","author":"Chesnokova","year":"2009","journal-title":"Proc Natl Acad Sci USA."},{"key":"B34","doi-asserted-by":"publisher","first-page":"13214","DOI":"10.1128\/JVI.05580-11","article-title":"Fusion of Epstein-Barr virus with epithelial cells can be triggered by alphavbeta5 in addition to alphavbeta6 and alphavbeta8, and integrin binding triggers a conformational change in glycoproteins gHgL","volume":"85","author":"Chesnokova","year":"2011","journal-title":"J Virol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1073\/pnas.77.5.2979","article-title":"Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen","volume":"77","author":"Hoffman","year":"1980","journal-title":"Proc Natl Acad Sci USA."},{"key":"B36","doi-asserted-by":"publisher","first-page":"5307","DOI":"10.1073\/pnas.77.9.5307","article-title":"Monoclonal antibodies against the major glycoprotein (gp350\/220) of Epstein-Barr virus neutralize infectivity","volume":"77","author":"Thorley-Lawson","year":"1980","journal-title":"Proc Natl Acad Sci USA."},{"key":"B37","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1128\/JVI.69.7.3987-3994.1995","article-title":"The Epstein-Barr virus (EBV) BZLF2 gene product associates with the gH and gL homologs of EBV and carries an epitope critical to infection of B cells but not of epithelial cells","volume":"69","author":"Li","year":"1995","journal-title":"J Virol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"9628","DOI":"10.1128\/JVI.00622-06","article-title":"Antibodies to gp350\/220 enhance the ability of Epstein-Barr virus to infect epithelial cells","volume":"80","author":"Turk","year":"2006","journal-title":"J Virol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.immuni.2018.03.026","article-title":"An antibody targeting the fusion machinery neutralizes dual-tropic infection and defines a site of vulnerability on Epstein-Barr Virus","volume":"48","author":"Snijder","year":"2018","journal-title":"Immunity"},{"key":"B40","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/infdis\/125.4.403","article-title":"Infectious mononucleosis: appearance of neutralizing antibody to Epstein-Barr virus measured by inhibition of formation of lymphoblastoid cell lines","volume":"125","author":"Miller","year":"1972","journal-title":"J Infect Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1128\/JVI.03001-14","article-title":"Epstein-Barr virus type 2 latently infects T cells, inducing an atypical activation characterized by expression of lymphotactic cytokines","volume":"89","author":"Coleman","year":"2015","journal-title":"J Virol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/infdis\/jix363","article-title":"Epstein-Barr virus type 2 infects t cells in healthy kenyan children","volume":"216","author":"Coleman","year":"2017","journal-title":"J Infect Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1158\/0008-5472.CAN-03-1562","article-title":"Epstein-Barr virus infection of human natural killer cell lines and peripheral blood natural killer cells","volume":"64","author":"Isobe","year":"2004","journal-title":"Cancer Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/318287a0","article-title":"Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine","volume":"318","author":"Epstein","year":"1985","journal-title":"Nature"},{"key":"B45","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/jmv.1890250209","article-title":"Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cottontop tamarins against EB virus-induced malignant lymphomas","volume":"25","author":"Morgan","year":"1988","journal-title":"J Med Virol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/jmv.1890290114","article-title":"Validation of a first-generation Epstein-Barr virus vaccine preparation suitable for human use","volume":"29","author":"Morgan","year":"1989","journal-title":"J Med Virol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1099\/0022-1317-73-2-449","article-title":"Protective immunization against Epstein-Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vector","volume":"73","author":"Finerty","year":"1992","journal-title":"J Gen Virol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1099\/0022-1317-74-3-501","article-title":"Replication-defective recombinant adenovirus expressing the Epstein-Barr virus (EBV) envelope glycoprotein gp340\/220 induces protective immunity against EBV-induced lymphomas in the cottontop tamarin","volume":"74","author":"Ragot","year":"1993","journal-title":"J Gen Virol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/0264-410X(94)90240-2","article-title":"Immunization of cottontop tamarins and rabbits with a candidate vaccine against the Epstein-Barr virus based on the major viral envelope glycoprotein gp340 and alum","volume":"12","author":"Finerty","year":"1994","journal-title":"Vaccine"},{"key":"B50","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/(SICI)1096-9071(199808)55:4<255::AID-JMV1>3.0.CO;2-#","article-title":"Immunization of common marmosets with Epstein-Barr virus (EBV) envelope glycoprotein gp340: effect on viral shedding following EBV challenge","volume":"55","author":"Cox","year":"1998","journal-title":"J Med Virol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1086\/590502","article-title":"A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses","volume":"198","author":"Yajima","year":"2008","journal-title":"J Infect Dis."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1084\/jem.20081720","article-title":"Priming of protective T cell responses against virus-induced tumors in mice with human immune system components","volume":"206","author":"Strowig","year":"2009","journal-title":"J Exp Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1086\/644644","article-title":"T cell-mediated control of Epstein-Barr virus infection in humanized mice","volume":"200","author":"Yajima","year":"2009","journal-title":"J Infect Dis."},{"key":"B54","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/978-3-319-22822-8_8","article-title":"EBV persistence\u2013introducing the virus","volume":"390","author":"Thorley-Lawson","year":"2015","journal-title":"Curr Top Microbiol Immunol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1128\/JVI.01416-06","article-title":"Epstein-Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes","volume":"81","author":"Wen","year":"2007","journal-title":"J Virol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1073\/pnas.0911948107","article-title":"AP-1 homolog BZLF1 of Epstein-Barr virus has two essential functions dependent on the epigenetic state of the viral genome","volume":"107","author":"Kalla","year":"2010","journal-title":"Proc Natl Acad Sci USA."},{"key":"B57","doi-asserted-by":"publisher","first-page":"e1002704","DOI":"10.1371\/journal.ppat.1002704","article-title":"The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination","volume":"8","author":"Jochum","year":"2012","journal-title":"PLoS Pathog."},{"key":"B58","doi-asserted-by":"publisher","first-page":"e1004656","DOI":"10.1371\/journal.ppat.1004656","article-title":"To be or not IIb: a multi-step process for Epstein-Barr virus latency establishment and consequences for B cell tumorigenesis","volume":"11","author":"Price","year":"2015","journal-title":"PLoS Pathog."},{"key":"B59","doi-asserted-by":"publisher","first-page":"386","DOI":"10.12688\/f1000research.10591.1","article-title":"Recent advances in understanding Epstein-Barr virus","volume":"6","author":"Stanfield","year":"2017","journal-title":"F1000Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e1005549","DOI":"10.1371\/journal.ppat.1005549","article-title":"Early T cell recognition of B cells following Epstein-Barr Virus Infection: identifying potential targets for prophylactic vaccination","volume":"12","author":"Brooks","year":"2016","journal-title":"PLoS Pathog."},{"key":"B61","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1084\/jem.20051287","article-title":"Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins","volume":"203","author":"Adhikary","year":"2006","journal-title":"J Exp Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1128\/JVI.02227-07","article-title":"Standardized and highly efficient expansion of Epstein-Barr virus-specific CD4+ T cells by using virus-like particles","volume":"82","author":"Adhikary","year":"2008","journal-title":"J Virol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1128\/JVI.02533-12","article-title":"An Epstein-Barr virus mutant produces immunogenic defective particles devoid of viral DNA","volume":"87","author":"Pavlova","year":"2013","journal-title":"J Virol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1084\/jem.176.1.169","article-title":"Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development","volume":"176","author":"Khanna","year":"1992","journal-title":"J Exp Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1084\/jem.176.1.157","article-title":"Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies","volume":"176","author":"Murray","year":"1992","journal-title":"J Exp Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"4896","DOI":"10.1128\/JVI.79.8.4896-4907.2005","article-title":"CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines","volume":"79","author":"Long","year":"2005","journal-title":"J Virol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/imm.12106","article-title":"Detection of Epstein-Barr virus-specific memory CD4+ T cells using a peptide-based cultured enzyme-linked immunospot assay","volume":"139","author":"Calarota","year":"2013","journal-title":"Immunology"},{"key":"B68","doi-asserted-by":"publisher","first-page":"e1002697","DOI":"10.1371\/journal.ppat.1002697","article-title":"Epstein-Barr virus infection of naive B cells in vitro frequently selects clones with mutated immunoglobulin genotypes: implications for virus biology","volume":"8","author":"Heath","year":"2012","journal-title":"PLoS Pathog."},{"key":"B69","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1200\/JCO.2011.39.8495","article-title":"Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation","volume":"31","author":"Icheva","year":"2013","journal-title":"J Clin Oncol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J Clin Oncol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/978-3-319-22834-1_15","article-title":"Adoptive T-Cell Immunotherapy","volume":"391","author":"Gottschalk","year":"2015","journal-title":"Curr Top Microbiol Immunol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1200\/JCO.2017.74.3179","article-title":"Tumor-specific T-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed hodgkin lymphoma","volume":"36","author":"Bollard","year":"2018","journal-title":"J Clin Oncol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"16544","DOI":"10.1073\/pnas.1400818111","article-title":"Efficient replication of Epstein-Barr virus in stratified epithelium in vitro","volume":"111","author":"Temple","year":"2014","journal-title":"Proc Natl Acad Sci USA."},{"key":"B74","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/35095584","article-title":"Epstein-Barr virus: exploiting the immune system","volume":"1","author":"Thorley-Lawson","year":"2001","journal-title":"Nat Rev Immunol."},{"key":"B75","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1128\/JVI.69.8.4872-4879.1995","article-title":"Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus","volume":"69","author":"Bogedain","year":"1995","journal-title":"J Virol."},{"key":"B76","doi-asserted-by":"crossref","first-page":"8644","DOI":"10.1128\/JVI.72.11.8644-8649.1998","article-title":"Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes","volume":"72","author":"Pepperl","year":"1998","journal-title":"J Virol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1002\/1521-4141(200009)30:9<2531::AID-IMMU2531>3.0.CO;2-O","article-title":"A global appraisal of immunodominant CD8 T cell responses to Epstein-Barr virus and cytomegalovirus by bulk screening","volume":"30","author":"Saulquin","year":"2000","journal-title":"Eur J Immunol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1086\/491741","article-title":"Differential targeting and shifts in the immunodominance of Epstein-Barr virus\u2013specific CD8 and CD4 T cell responses during acute and persistent infection","volume":"192","author":"Woodberry","year":"2005","journal-title":"J Infect Dis."},{"key":"B79","doi-asserted-by":"publisher","first-page":"92","DOI":"10.4049\/jimmunol.1100590","article-title":"Cytotoxic CD4+ T cell responses to EBV contrast with CD8 responses in breadth of lytic cycle antigen choice and in lytic cycle recognition","volume":"187","author":"Long","year":"2011","journal-title":"J Immunol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"5398","DOI":"10.4049\/jimmunol.1301629","article-title":"CD8+ T cell responses to lytic EBV infection: late antigen specificities as subdominant components of the total response","volume":"191","author":"Abbott","year":"2013","journal-title":"J Immunol."},{"key":"B81","first-page":"1","article-title":"Antibody-dependent cellular cytotoxicity (ADCC) against Epstein-Barr virus-determined membrane antigens","volume":"25","author":"Jondal","year":"1976","journal-title":"Clin Exp Immunol."},{"key":"B82","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1128\/JVI.41.1.258-264.1982","article-title":"Production and characterization of monoclonal antibodies against the Epstein-Barr virus membrane antigen","volume":"41","author":"Strnad","year":"1982","journal-title":"J Virol."},{"key":"B83","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1128\/JVI.65.2.996-1001.1991","article-title":"Epstein-Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBV-specific antibody-dependent cellular cytotoxicity","volume":"65","author":"Khyatti","year":"1991","journal-title":"J Virol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"656","DOI":"10.4049\/jimmunol.1601574","article-title":"Antibody-dependent NK cell activation differentially targets EBV-infected cells in lytic cycle and bystander B lymphocytes bound to viral antigen-containing Particles","volume":"199","author":"Lopez-Montanes","year":"2017"},{"key":"B85","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1177\/2051013613515621","article-title":"Successes and challenges in varicella vaccine","volume":"2","author":"Papaloukas","year":"2014","journal-title":"Ther Adv Vaccines"},{"key":"B86","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1177\/2051013616655980","article-title":"Efficacy of varicella (VZV) vaccination: an update for the clinician","volume":"4","author":"Wang","year":"2016","journal-title":"Ther Adv Vaccines"},{"key":"B87","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/82_2010_31","article-title":"VZV T cell-mediated immunity","volume":"342","author":"Weinberg","year":"2010","journal-title":"Curr Top Microbiol Immunol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1093\/infdis\/165.5.852","article-title":"Kinetics and viral protein specificity of the cytotoxic T lymphocyte response in healthy adults immunized with live attenuated varicella vaccine","volume":"165","author":"Sharp","year":"1992","journal-title":"J Infect Dis."},{"key":"B89","doi-asserted-by":"crossref","first-page":"636","DOI":"10.4049\/jimmunol.142.2.636","article-title":"T lymphocyte cytotoxicity with natural varicella-zoster virus infection and after immunization with live attenuated varicella vaccine","volume":"142","author":"Diaz","year":"1989","journal-title":"J Immunol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1089\/088282402760312377","article-title":"Memory cytotoxic T cell responses to viral tegument and regulatory proteins encoded by open reading frames 4, 10, 29, and 62 of varicella-zoster virus","volume":"15","author":"Arvin","year":"2002","journal-title":"Viral Immunol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"5554","DOI":"10.1016\/j.vaccine.2016.09.051","article-title":"Marek's disease herpesvirus vaccines integrate into chicken host chromosomes yet lack a virus-host phenotype associated with oncogenic transformation","volume":"34","author":"McPherson","year":"2016","journal-title":"Vaccine"},{"key":"B92","doi-asserted-by":"publisher","first-page":"4695","DOI":"10.1016\/j.vaccine.2017.07.048","article-title":"Recombinant Gallid herpesvirus 2 with interrupted meq genes confers safe and efficacious protection against virulent field strains","volume":"35","author":"Zhang","year":"2017","journal-title":"Vaccine"},{"key":"B93","doi-asserted-by":"publisher","first-page":"126","DOI":"10.2307\/1588906","article-title":"Control of Marek's disease in the Netherlands","volume":"16","author":"Rispens","year":"1972","journal-title":"Avian Dis."},{"key":"B94","doi-asserted-by":"publisher","first-page":"15016","DOI":"10.1038\/nrdp.2015.16","article-title":"Varicella zoster virus infection","volume":"1","author":"Gershon","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"B95","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13567-016-0404-3","article-title":"Marek's disease in chickens: a review with focus on immunology","volume":"47","author":"Boodhoo","year":"2016","journal-title":"Vet Res."},{"key":"B96","doi-asserted-by":"publisher","first-page":"107fs107","DOI":"10.1126\/scitranslmed.3002878","article-title":"Epstein-Barr virus: an important vaccine target for cancer prevention","volume":"3","author":"Cohen","year":"2011","journal-title":"Sci Transl Med."},{"key":"B97","doi-asserted-by":"publisher","first-page":"S196","DOI":"10.1086\/522131","article-title":"Risk of herpes zoster in adults immunized with varicella vaccine","volume":"197","author":"Hambleton","year":"2008","journal-title":"J Infect Dis."},{"key":"B98","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.virol.2009.03.030","article-title":"EBV BMRF-2 facilitates cell-to-cell spread of virus within polarized oral epithelial cells","volume":"388","author":"Xiao","year":"2009","journal-title":"Virology"},{"key":"B99","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1146\/annurev.mi.27.100173.002213","article-title":"The EB virus","volume":"27","author":"Epstein","year":"1973","journal-title":"Annu Rev Microbiol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1093\/jnci\/56.4.697","article-title":"Epstein-Barr Virus \u2014 is it time to develop a vaccine program?","volume":"56","author":"Epstein","year":"1976","journal-title":"J Nat Cancer Instit."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1182\/blood-2008-03-148072","article-title":"Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses","volume":"112","author":"Gurer","year":"2008","journal-title":"Blood"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1182\/blood-2014-07-591412","article-title":"Antigen-armed antibodies targeting B lymphoma cells effectively activate antigen-specific CD4+ T cells","volume":"125","author":"Yu","year":"2015","journal-title":"Blood"},{"key":"B103","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41375-018-0160-7","article-title":"Antibodies conjugated with viral antigens elicit a cytotoxic T cell response against primary CLL ex vivo Leukemia","volume":"33","author":"Schneidt","year":"2018"},{"key":"B104","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1016\/j.vaccine.2013.04.071","article-title":"A novel tetrameric gp350 1-470 as a potential Epstein-Barr virus vaccine","volume":"31","author":"Cui","year":"2013","journal-title":"Vaccine"},{"key":"B105","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1016\/j.vaccine.2016.06.021","article-title":"Rabbits immunized with Epstein-Barr virus gH\/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350","volume":"34","author":"Cui","year":"2016","journal-title":"Vaccine"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.cell.2015.07.043","article-title":"Rational design of an Epstein-Barr virus vaccine targeting the receptor-binding site","volume":"162","author":"Kanekiyo","year":"2015","journal-title":"Cell"},{"key":"B107","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12967-015-0415-2","article-title":"A chimeric EBV gp350\/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice","volume":"13","author":"Ogembo","year":"2015","journal-title":"J Transl Med."},{"key":"B108","doi-asserted-by":"publisher","first-page":"19255","DOI":"10.18632\/oncotarget.13770","article-title":"Novel Epstein-Barr virus-like particles incorporating gH\/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice","volume":"8","author":"Perez","year":"2017","journal-title":"Oncotarget"},{"key":"B109","doi-asserted-by":"publisher","first-page":"13105","DOI":"10.1128\/JVI.05598-11","article-title":"A virus-like particle-based Epstein-Barr virus vaccine","volume":"85","author":"Ruiss","year":"2011","journal-title":"J Virol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"e1007464","DOI":"10.1371\/journal.ppat.1007464","article-title":"Immunogenic particles with a broad antigenic spectrum stimulate cytolytic T cells and offer increased protection against EBV infection ex vivo and in mice","volume":"14","author":"van Zyl","year":"2018","journal-title":"PLoS Pathog"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/S0161-5890(97)00143-0","article-title":"Immunoglobulin as a vehicle for foreign antigenic peptides immunogenic to T cells","volume":"34","author":"Lunde","year":"1997","journal-title":"Mol Immunol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S0966-842X(03)00208-7","article-title":"Virus-like particles as immunogens","volume":"11","author":"Noad","year":"2003","journal-title":"Trends Microbiol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/eji.200425749","article-title":"High epitope density in a single protein molecule significantly enhances antigenicity as well as immunogenicity: a novel strategy for modern vaccine development and a preliminary investigation about B cell discrimination of monomeric proteins","volume":"35","author":"Liu","year":"2005","journal-title":"Eur J Immunol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"E501","DOI":"10.1208\/aapsj080359","article-title":"Effects of protein aggregates: an immunologic perspective","volume":"8","author":"Rosenberg","year":"2006","journal-title":"Aaps J."},{"key":"B115","doi-asserted-by":"publisher","first-page":"244","DOI":"10.7150\/ntno.19796","article-title":"Nanoparticle vaccines adopting virus-like features for enhanced immune potentiation","volume":"1","author":"Chattopadhyay","year":"2017","journal-title":"Nanotheranostics"},{"key":"B116","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.csbj.2015.11.001","article-title":"Self-assembling protein nanoparticles in the design of vaccines","volume":"14","author":"Lopez-Sagaseta","year":"2016","journal-title":"Comput Struct Biotechnol J."},{"key":"B117","doi-asserted-by":"publisher","first-page":"5188","DOI":"10.1073\/pnas.96.9.5188","article-title":"A first-generation packaging cell line for Epstein-Barr virus-derived vectors","volume":"96","author":"Delecluse","year":"1999","journal-title":"Proc Natl Acad Sci USA."},{"key":"B118","doi-asserted-by":"publisher","first-page":"7641","DOI":"10.1128\/JVI.79.12.7641-7647.2005","article-title":"Defective infectious particles and rare packaged genomes produced by cells carrying terminal-repeat-negative epstein-barr virus","volume":"79","author":"Feederle","year":"2005","journal-title":"J Virol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"15036","DOI":"10.1073\/pnas.232381299","article-title":"Glycoprotein gp110 of Epstein-Barr virus determines viral tropism and efficiency of infection","volume":"99","author":"Neuhierl","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"B120","doi-asserted-by":"publisher","first-page":"4616","DOI":"10.1128\/JVI.01613-08","article-title":"Primary B-cell infection with a deltaBALF4 Epstein-Barr virus comes to a halt in the endosomal compartment yet still elicits a potent CD4-positive cytotoxic T-cell response","volume":"83","author":"Neuhierl","year":"2009","journal-title":"J Virol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"581","DOI":"10.5732\/cjc.014.10197","article-title":"Epstein-Barr virus and nasopharyngeal carcinoma","volume":"33","author":"Young","year":"2014","journal-title":"Chin J Cancer"},{"key":"B122","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1146\/annurev-immunol-032414-112326","article-title":"The immunology of Epstein-Barr virus-induced disease","volume":"33","author":"Taylor","year":"2015","journal-title":"Annu Rev Immunol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"23","DOI":"10.21037\/cco.2016.03.20","article-title":"Therapeutic vaccination strategies to treat nasopharyngeal carcinoma","volume":"5","author":"Taylor","year":"2016","journal-title":"Chin Clin Oncol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1002\/1097-0215(20001215)88:6<949::AID-IJC18>3.0.CO;2-6","article-title":"Heterogeneity of HLA and EBER expression in Epstein-Barr virus-associated nasopharyngeal carcinoma","volume":"88","author":"Yao","year":"2000","journal-title":"Int J Cancer"},{"key":"B125","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1615\/CritRevOncog.2018027528","article-title":"Immunotherapy for EBV-associated nasopharyngeal carcinoma","volume":"23","author":"Hong","year":"2018","journal-title":"Crit Rev Oncog."},{"key":"B126","first-page":"6952","article-title":"Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma","volume":"62","author":"Lin","year":"2002","journal-title":"Cancer Res."},{"key":"B127","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/annonc\/mdr341","article-title":"A phase II study evaluating the safety and efficacy of an adenovirus-DeltaLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma","volume":"23","author":"Chia","year":"2012","journal-title":"Ann Oncol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1158\/0008-5472.CAN-12-2448","article-title":"Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients","volume":"73","author":"Hui","year":"2013","journal-title":"Cancer Res."},{"key":"B129","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1158\/1078-0432.CCR-14-1122-T","article-title":"A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer","volume":"20","author":"Taylor","year":"2014","journal-title":"Clin Cancer Res."},{"key":"B130","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/978-3-319-22822-8_7","article-title":"Epstein-Barr Virus: from the detection of sequence polymorphisms to the recognition of viral types","volume":"390","author":"Feederle","year":"2015","journal-title":"Curr Top Microbiol Immunol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00262-018-2118-z","article-title":"Epstein-Barr virus strain heterogeneity impairs human T-cell immunity","volume":"67","author":"Cirac","year":"2018","journal-title":"Cancer Immunol Immunother."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00104\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T22:44:35Z","timestamp":1694645075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00104\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,25]]},"references-count":131,"alternative-id":["10.3389\/fonc.2019.00104"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.00104","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,25]]},"article-number":"104"}}